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David Moher1,2Abstract
Transparently documenting who and why a person is an author of a clinical trial report, as with any other article, is
important since it allows research team members appropriate recognition and also likely helps reduce or avoid
problems such as ghost authorship. Marušić and colleagues have previously proposed a five-step framework for
attributing authorship of pharmaceutical company-sponsored clinical trials. The process is short, easily implemented,
and can be used in addition to the authorship guidance provided by the International Committee of Medical
Journal Editors. For the framework to gain optimal traction it is important that a strong implementation plan is
developed and carried out across a broad spectrum of stakeholders. Authorship brings with it important responsibilities;
authors must ensure that articles baring their names must be fit for purpose. This will help guarantee an increased
value for published reports of clinical trials.
Please see related article: http://www.biomedcentral.com/1741-7015/12/197
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“Complexity is the enemy of transparency” [1]. Today,
BMC Medicine publishes another paper on journalology
(publication science) [2]. Attributing authorship, and
authorship order, is complex and often a ‘black box’ for
prospective authors. Professor Marušić and colleagues
have tried to peel back the black box concerning the
assigning of authorship for industry-sponsored clinical
trials. Their methods are good and reported in sufficient
detail to allow interested readers to replicate them [3].
The research team have used an integrated knowledge
translation approach to developing their proposed five-
steps for transparently disclosing authorship. Participants
from pharmaceutical companies that conduct clinical trials,
academics, editors, and the Medical Publishing Insights and
Practices initiative were involved in the entire process;
this facilitates buy-in and support for the process and out-
come. These same people are likely to become front-line
ambassadors and early adopters for disseminating andCorrespondence: dmoher@ohri.ca
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unless otherwise stated.implementing the five-step framework within their own
working environments, and hopefully, more broadly.
What is positive about this research is that the pro-
posed attribution process for authorship is brief, and not
complex; it’s only five-steps. It is meant to augment the
guidance provided by the International Committee of
Medical Journal Editors [4]. To enhance uptake of the
framework it will be important for the team, or others,
to develop a bank of worked examples for each step in
the five-step process. Using worked examples from
specific trials will likely facilitate implementation. The
authors have started the process with seven case examples
included in their publication. A dedicated website for the
framework whereby authorship examples can be submitted
by pharmaceutical companies and others, vetted and added
to a bank of examples, freely accessible to anybody, is worth
considering. This will help prospective clinical trialists en-
sure a transparent process in deciding on authorship.
If this authorship initiative is to be successful it requires
endorsement and, more importantly, implementation. As
Marušić and colleagues note [2], previous efforts, such as
contributorship, have not been broadly implemented. What
is less clear is how the proposed framework is going to be
endorsed and implemented. Important initial steps should
include strong and consistent language of endorsementhis is an Open Access article distributed under the terms of the Creative
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development of the five-step process. Support and endorse-
ment from umbrella groups, such as the Pharmaceutical
Research and Manufacturers of America [5], and others
such as CONSORT [6], is also worth considering. While
endorsement is a useful step, it is difficult to measure and
likely not the most relevant outcome. More important will
be to develop plans based on appropriately developed ap-
proaches [7,8] to implement the framework. This is likely
to be most effective when pharmaceutical companies mod-
ify their authorship practices and polices when conducting
any clinical trial. An effective policy would require all clin-
ical trials to implement the five-step framework at their in-
ception. Without strong implementation the framework is
less likely to affect positive change. This has been observed
when trying to implement reporting guidelines in bio-
medical journals [9,10]. Part of any implementation plan
also needs to include an evaluation of the framework. It
is important to collect data that will inform its useful-
ness. There is little merit in maintaining policies that
are not supported by evidence.
Marušić et al. are silent on whether their framework
can be used when developing authorship for submitting
clinical trial protocols for publication consideration [2].
Making clinical trial protocols accessible is important
and at least one Biomed Central journal – Trials – regu-
larly publishes them. Additionally, with the requirement
of trial registration, this framework could also be used
when completing the investigator information part of
the registration.
Most of us are not born authors. It is an acquired skill
that often starts during graduate school. This is where all
journalology issues, including those pertaining to author-
ship issues (e.g., attributing authorship, authorship order,
and ghost and guest authorship, author responsibilities)
should be formally taught and discussed. Developing such
skills early can translate into something useful throughout a
researcher’s (author’s) career. It is unfortunate that almost
all universities, and other centres of higher learning, appear
to have abdicated their responsibilities regarding formally
teaching journalology; the irony is not lost on me. These
institutions are the very same places developing the next
generation of biomedical researchers. Universities need to
set aside appropriate resources to enable and promote
such courses, and others, related to journalology [11].
While authors have rights and privileges, they also
have important responsibilities that require much greater
attention. Given the opportunity of authorship, it is equally
important to assert this responsibility. Authors must ensure
that papers baring their name are “fit for purpose” [12].
Here, authors need to ensure that every report baring their
name is a completely reported and transparent account
of what was done (methods) and found (results) to en-
able interested readers to replicate the methods and usethe results. Collectively, authors have not performed
appropriately with regards to reporting their clinical
trials. This avoidable waste is troublesome for share-
holders of publicly traded pharmaceutical companies
and tax payers of publicly-funded clinical trials. It is
not a good return of a fiscal investment when reports
of trials are so inadequate that their results cannot be
used. For example, Duff et al. [13] examined 262 reports of
trials from the most prominent oncology journals assessing
them for 10 essential elements regarding the description of
their interventions, such as the drug’s name and route of
administration. The authors reported that only 11% of the
articles reported all 10 characteristics. Although we have
seen improvements over time in reporting the unique
characteristics of randomized trials – sequence generation,
allocation concealment, and implementation – these items
are adequately reported in less than half of the trial re-
ports [14]. In some clinical specialties, the situation is
much worse [15].
Disclosing authorship transparently is important for
any manuscript being submitted to a biomedical journal
for publication consideration. The responsibilities associ-
ated with authorship must be taken seriously. This might
help increase value and reduce avoidable waste of bio-
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